Clinical trials: Selective Estrogen Receptor Modulator
Healthy
Comparison of Blood Levels of Two Formulations of the Selective Hormone Receptor Modulator CDB-2914
This study will compare blood levels of the drug CDB-2914 in healthy women receiving the compound in crystalline powder form with the blood levels of women receiving an identical dose of the drug in micronized form.
- Trial name
- NCT00041899
- Testing
- CDB-2914, COB-2914
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Leiomyoma
Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914
This study will evaluate whether the experimental drug ulipristal acetate can shrink uterine fibroids in pre-menopausal women.
- Trial name
- NCT00290251
- Testing
- ulipristal acetate 20 mg, ulipristal acetate 10 mg
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cognition, Aging
Cognition in the Study of Tamoxifen and Raloxifene
The purpose of this study is to assess the effects of tamoxifen and raloxifene on cognitive aging in selected cognitively-healthy women.
- Trial name
- Co-STAR (NCT00687102)
- Testing
- tamoxifen, raloxifene
- Where
- 134 sites in United States, Canada
- Volunteers
- 1,498 people, healthy volunteers welcome
- Sponsor
- Wake Forest University
Breast Pain
The Effect of Toremifene Treatment to the Magnetic Resonance Imaging (MRI) Findings in Premenstrual Mastalgia
The purpose of this study is to determine the effect of toremifene treatment to the MRI findings of the breast in women suffering from premenstrual mastalgia.
- Trial name
- NCT00534846
- Testing
- toremifene
- Where
- Finland
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Satakunta Central Hospital
Postmenopause
Use of the Synthetic Hormone CDB-2914 in Treating Symptoms of Menopause
This study will examine the safety and effectiveness of a synthetic hormone, CDB-2914, for treating symptoms of menopause. It will compare the effects of estrogen and CDB-2914 with those of estrogen and progesterone in…
- Trial name
- NCT00009659
- Testing
- CDB 2914
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Breast Cancer
Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer
Preclinical data has demonstrated that entinostat (SNDX-275) can enhance fulvestrant sensitivity in hormone receptor-positive breast cancer in animal models.
- Trial name
- ENCORE305 (NCT02115594)
- Testing
- Fulvestrant, Entinostat
- Where
- United States
- Sponsor
- Syndax Pharmaceuticals
Selective Estrogen Receptor Modulator
Comparison Between Raloxifene and Bazedoxifene
Although there are two kinds of selective estrogen receptor modulator (SERM) :raloxifene (RLX) and bazedoxifene (BZA), the difference is still unclear.
- Trial name
- NCT01973738
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Toshihiko Kono
Androgen Receptor Positive, Estrogen Receptor Negative
Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer
This phase II trial studies the side effects and how well pembrolizumab and enobosarm work in treating patients with androgen receptor positive triple negative breast cancer that has spread to other places in the body…
- Conditions
- Androgen Receptor Positive, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02971761
- Testing
- Enobosarm, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Schizophrenia, Schizoaffective Disorder
Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia
The aim of the project is to investigate the use of Raloxifene (a new form of estrogen) in the treatment of young women with schizophrenia and schizoaffective disorder.
- Trial name
- NCT02354001
- Testing
- Raloxifene hydrochloride
- Where
- Australia
- Volunteers
- 80 people
- Sponsor
- The Alfred
Selective Estrogen Receptor Modulator (SERM)
The Effects of Seasonal Changes in Osteoporosis Treatment
There are few reports concerning to the seasonal variation of osteoporosis treatment. In this study, we plan to compare clinical efficacy and safety by seasons.
- Trial name
- NCT02977949
- Testing
- Raloxifene
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Toshihiko Kono
Leiomyoma
Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist
Uterine leiomyomata (fibroids) are a common benign tumor of the uterine muscle in premenopausal women. These tumors may cause bleeding, pelvic pain and pressure.
- Trial name
- NCT00044876
- Testing
- CDB-2914
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Breast Neoplasms, Medication Adherence
A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)
Background: In women with hormone receptor positive (HR+) breast cancer, adjuvant endocrine therapy (AET) is associated with a significant survival advantage.
- Trial name
- NCT02876848
- Testing
- OPTIMUM e-health tool
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Breast Cancer, Breast Carcinoma
Therapeutic Dose Monitoring (TDM) of Tamoxifen
Tamoxifen is a potent and effective drug reducing the risk of dying from breast cancer in the adjuvant setting. Although more modern drugs have partly replaced tamoxifen, it is helpful in the neoadjuvant and metastatic settings…
- Conditions
- Breast Cancer, Breast Carcinoma, Breast Tumors, Cancer of Breast
- Trial name
- NCT05133674
- Testing
- Tamoxifen 20 mg
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska University Hospital
Breast Cancer
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of LY353381 may be an effective way to prevent the development of breast cancer in women who have…
- Trial name
- NCT00005879
- Testing
- arzoxifene
- Where
- 2 sites in United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Vasomotor Symptoms (VMS)
Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen
Open-label, two dose study of Q-122, over a 4 week treatment period to explore the effects of Q-122 in a population of women with a history of breast cancer taking an aromatase inhibitor or tamoxifen.
- Trial name
- NCT04080297
- Testing
- oral capsule of Q-122
- Volunteers
- 21 people
- Sponsor
- Que Oncology
Breast Cancer
Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer
Phase II trial to explore the efficacy of vorinostat and tamoxifen combined.
- Trial name
- NCT00365599
- Testing
- suberoylanilide hydroxamic acid (SAHA, Vorinostat), tamoxifen citrate (Tamoxifen)
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute